 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Omnicell, Inc. (OMCL) provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide.
It operates in two segments, Automation and Analytics, and Medication Adherence.
The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications.
The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes.
On April 25th, Omnicell (OMCL) reported 1st Quarter March 2019 earnings of $0.43 per share on revenue of $202.5 million. The consensus earnings estimate was $0.23 per share on revenue of $199.4 million. Revenue grew 10.9% on a year-over-year basis.
The company said it expects second quarter earnings of $0.61 to $0.66 per share on revenue of $211.0 million to $217.0 million. The current consensus earnings estimate is $0.56 per share on revenue of $212.7 million for the quarter ending June 30, 2019. The company also said it now expects 2019 earnings of $2.62 to $2.82 per share and continues to expect revenue of $880.0 million to $900.0 million. The company's previous guidance was earnings of $2.40 to $2.60 per share and the current consensus earnings estimate is $2.55per share on revenue of $892.3 million for the year ending December 31, 2019.
Shares have broken above the resistance level of $85.. Higher share prices are expected.
Entry Point: $86.75
Stop Loss: $82.00
Trading Range: $49.45 - $86.97
Target Price: $95.45
OMCL closed at $70
